Vera Therapeutics Income Statement (2020-2026) | VERA

Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating items
Research & Development (Quarter)
3.23M3.56M-2.73M12.55M10.11M3.70M65.29M25.11M16.23M16.10M20.79M23.20M29.31M40.31M33.35M41.28M58.20M56.47M59.31M86.01M
Selling, General & Administrative (Quarter)
2.61M3.69M3.83M4.47M4.95M5.59M6.91M6.15M5.74M5.66M6.24M7.91M8.03M9.49M15.57M15.92M21.95M27.46M34.90M39.12M
Restructuring Costs (Quarter)
0.03M-0.12M
Other Operating Expenses (Quarter)
2.69M15.96M
Operating Expenses (Quarter)
5.85M7.25M16.59M17.02M15.06M25.24M33.58M31.26M21.97M21.76M27.03M31.11M37.34M49.80M48.91M57.19M80.14M83.93M94.21M125.13M
Operating Income (Quarter)
-5.85M-7.25M-16.59M-17.02M-15.06M-25.24M38.62M-31.26M-21.97M-21.76M54.83M-31.11M-37.34M-49.80M86.31M-57.19M-80.14M-83.93M-94.21M-125.13M
EBIT (Quarter)
-5.85M-7.25M-16.59M-17.02M-15.06M-25.24M38.62M-31.26M-21.97M-21.76M54.83M-31.11M-37.34M-49.80M86.31M-57.19M-80.14M-83.93M-94.21M-125.13M
Non-operating items
Interest & Investment Income (Quarter)
0.00M0.01M0.01M0.03M0.26M0.57M0.89M1.62M2.24M2.16M1.96M4.19M5.10M4.76M6.66M6.91M6.32M5.74M5.52M6.36M
Non Operating Income (Quarter)
2.41M-0.36M-0.26M-0.06M0.20M0.56M1.14M1.19M1.81M1.65M1.37M2.73M3.63M3.17M5.49M5.50M3.61M3.64M3.11M4.10M
Net income details
EBT (Quarter)
-5.85M-7.25M-16.60M-17.11M-14.92M-24.82M38.91M-30.51M-20.64M-20.54M55.73M-28.83M-34.15M-46.98M91.10M-52.08M-75.69M-80.16M-90.59M-120.60M
Profit After Tax (Quarter)
-3.44M-7.61M-16.85M-17.09M-14.85M-24.68M-32.44M-30.07M-20.16M-20.10M-25.66M-28.38M-33.71M-46.63M-43.42M-51.69M-76.53M-80.29M-91.10M-121.03M
Equity Income (Quarter)
-0.28M-0.36M-0.25M-0.29M-0.26M-0.20M-0.06M-0.00M-0.03M-0.01M-0.00M-0.00M-0.01M
Income from Continuing Operations (Quarter)
-5.85M-7.25M-16.60M-17.11M-14.92M-24.82M38.91M-30.51M-20.64M-20.54M55.73M-28.83M-34.15M-46.98M91.10M-52.08M-75.69M-80.16M-90.59M-120.60M
Consolidated Net Income (Quarter)
-5.85M-7.25M-16.60M-17.11M-14.92M-24.82M38.91M-30.51M-20.64M-20.54M55.73M-28.83M-34.15M-46.98M91.10M-52.08M-75.69M-80.16M-90.59M-120.60M
Income towards Parent Company (Quarter)
-5.85M-7.25M-16.60M-17.11M-14.92M-24.82M38.91M-30.51M-20.64M-20.54M55.73M-28.83M-34.15M-46.98M91.10M-52.08M-75.69M-80.16M-90.59M-120.60M
Net Income towards Common Stockholders (Quarter)
-5.85M-7.25M-16.60M-17.11M-14.92M-24.82M38.91M-30.51M-20.64M-20.54M55.73M-28.83M-34.15M-46.98M91.10M-52.08M-75.69M-80.16M-90.59M-120.60M
Additional items
EPS (Basic) (Quarter)
-0.33-0.36-0.97-0.71-0.55-0.91-1.19-0.80-0.46-0.45-0.58-0.56-0.62-0.85-0.72-0.81-1.20-1.26-1.39-1.69
EPS (Weighted Average and Diluted) (Quarter)
-0.33-0.36-0.97-0.71-0.55-0.91-1.19-0.80-0.46-0.45-0.58-0.56-0.62-0.85-0.72-0.81-1.20-1.26-1.39-1.69
Shares Outstanding (Weighted Average) (Quarter)
10.50M10.79M13.44M24.23M25.66M27.22M26.57M37.67M44.27M42.12M42.71M50.97M54.73M53.54M55.33M63.67M63.79M63.85M64.23M71.48M
Shares Outstanding (Diluted Average) (Quarter)
5.47M10.79M13.44M24.23M25.66M27.22M26.57M37.67M40.99M42.12M42.71M50.97M52.85M53.54M55.33M63.67M63.73M63.85M64.23M71.48M
EBITDA (Quarter)
-5.85M-7.25M-16.59M-17.02M-14.99M-24.81M-32.38M-29.85M-20.30M-20.04M-25.55M-28.81M-33.98M-45.14M-44.08M-51.43M-76.66M-79.94M-91.19M-121.97M
Interest Expenses (Quarter)
0.02M0.12M0.13M0.15M0.60M0.87M0.91M0.94M1.06M1.91M1.91M1.94M1.87M1.79M1.87M1.96M1.90M1.82M